Resistance mechanism to Notch inhibition and combination therapy in human T-cell acute lymphoblastic leukemia

Gain-of-function mutations in NOTCH1 are among the most frequent genetic alterations in T-cell acute lymphoblastic leukemia (T-ALL), highlighting the Notch signaling pathway as a promising therapeutic target for personalized medicine. Yet, a major limitation for longterm success of targeted therapy is relapse due to tumor heterogeneity or acquired resistance. Thus, we performed a genome-wide CRISPR-Cas9 screen to identify prospective resistance mechanisms to pharmacological NOTCH inhibitors and novel targeted combination therapies to efficiently combat T-ALL. Mutational loss of phosphoinositide-3kinase regulatory subunit 1 (PIK3R1) causes resistance to Notch inhibition. PIK3R1 deficiency leads to increased PI3K/AKT signaling, which regulates cell cycle and the spliceosome machinery, both at the transcriptional and posttranslational level. Moreover, several therapeutic combinations have been identified, in which simultaneous targeting of the cyclin-dependent kinases 4 and 6 (CDK4/6) and NOTCH proved to be the most efficacious in T-ALL xenotransplantation models.

Automated summary

Gain-of-function mutations in NOTCH1 are common in T-cell acute lymphoblastic leukemia (T-ALL) and targeting the Notch signaling pathway has shown promise for personalized medicine. Resistance to Notch inhibitors can occur due to mutational loss of PIK3R1, resulting in increased PI3K/AKT signaling. Combination therapy targeting CDK4/6 and NOTCH has been found to be the most effective in T-ALL xenotransplantation models.